PRESIDE is the first evidence that docetaxel might reduce enzalutamide resistance when given together. It also suggests that triplet therapy may be helpful in men who have already developed castration resistance.
Adding A Platinum Drug to Chemotherapy
The study concluded that adding Carboplatin to cabazitaxel showed improved clinical efficacy compared with cabazitaxel alone for men with metastatic castration-resistant prostate cancer. Although adverse events were more common with the combination, the treatment was safe and generally well-tolerated.
Relugolix - An Oral Lupron Like Drug – On The Horizon
Myovant Sciences has developed an alternative gonadotropin-releasing hormone (GnRH) antagonist named relugolix. Their still investigational treatment is an oral (taken by mouth) as opposed to an injectable gonadotropin-releasing hormone (GnRH) antagonist. It has completed a very successful phase III clinical trial called HERO has been submitted to the FDA for approval. We at Cancer ABCs believe relugolix will be approved by the FDA shortly.
Phase III HERO Study Meets Primary Efficacy Endpoint in Men with Advanced Prostate Cancer
What Treatment After Zytiga or Xtandi and Chemotherapy Fail?
Apalutamide (Erleada® ) Approved for Metastatic Castrate Sensitive Prostate Cancer
PROCEED Registry Show Men with Low PSA Scores Have a Median Survival Longer Then Four Years
Using Radioactive Particles to Kill Cells Attached to a ‘Homing Device’ to Seek Out Cancers
Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.
An emerging class of drugs are made up of a radioactive particle that can kill cells attached to a ‘homing device’ to seek out cancers by detecting the presence of a target molecule on their surface.
Metastatic Prostate Cancer Co-Pay Fund Open
The FDA Approves Darolutamide
Germline Mutations As Prognostic Indicators of Castrate Resistance
Evaluating PSMA-Targeted Radionuclide Therapy
Is There A Role for Testosterone Therapy in the Treatment of Metastatic Prostate Cancer?
There has long been a discussion about the possible effects of using testosterone as a treatment for men with advanced metastatic prostate cancer. In a poster presentation at ASCO 2019, it was shown that there are androgen receptor changes in the circulating-tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.
Is ADT Necessary Along with Zytiga?
ADT With and Without Xtandi in Men with Metastatic Hormone Sensitive Prostate Cancer: The ARCHES Trial
Darolutamide - Great Results From The ARAMIS Trial For Men With M0 Prostate Cancer
The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.